1256584-74-3Relevant articles and documents
Preparation method of alectinib
-
, (2020/01/08)
The invention provides a preparation method of alectinib. The method comprises the following steps: taking 3-(4-ethylphenyl)-3-methylbutane-2-one as an initial raw material, carrying out an iodinationreaction on the initial raw material and an iodination reagent, and reacting obtained 3-(3-iodo-4-ethylphenyl)-2-methylbutane-2-one with a carbonylation reagent; carrying out a substitution reactionon obtained 4-(3-iodo-4-ethylphenyl)-4-methyl-3-oxovalerate and 4-chloro-3-nitro-benzonitrile in an alkaline environment, carrying out a reduction condensation reaction on obtained 4-(3-iodo-4-ethylphenyl)-2-(2-nitro-4-cyanophenyl)-4-methyl-3-oxovalerate, carrying out a cyclization reaction on obtained 6-cyano-2-(2-(4-ethyl-3-iodophenyl)prop-2-yl)-1H-methyl indole-3-carboxylate, and carrying out asubstitution reaction on obtained 9-ethyl-8-iodo-6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile and 4-(4-piperidyl)morpholine to obtain a finished product, namely the alectinib.The preparation method of alectinib has the main beneficial effects that the raw materials are cheap and are easy to obtain, the synthetic route is simple, the synthetic process is green and environmentally friendly, and industrial production is facilitated.
IMPROVED PROCESS FOR THE PREPARATION OF 9-ETHYL-6,6-DIMETHYL-8-[4-(MORPHOLIN-4-YL) PIPERIDIN-1-YL]-11-OXO-6,11-DIHYDRO-5H-BENZO[B]CARBAZOLE-3-CARBONITRILE HYDROCHLORIDE
-
Page/Page column 20; 28, (2019/11/19)
The present invention relates to novel process for the preparation of 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride compound of formula-1a, represented by the following structural formula: The present invention also provides an improved process for the preparation of tert-butyl-4-(4-ethyl-3-iodophenyl)-4-methyl-3-oxopentanoate having the following structural formula which is useful in the preparation of Alectinib and its pharmaceutical acceptable salts.